Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Hormone Receptor Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Not applicableStudy completedNCT04916509
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Who this might be right for
Breast Neoplasms
Pfizer 258
Testing effectiveness (Phase 2)Looking for participantsNCT05573126
What this trial is testing

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Who this might be right for
Hormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerMetastatic Breast Cancer
Ellipses Pharma 95
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Ended earlyNCT04789668
What this trial is testing

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Hematopoietic and Lymphoid Cell Neoplasm+11 more
M.D. Anderson Cancer Center 8
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)Looking for participantsNCT07112053
What this trial is testing

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast Carcinoma
University of Washington 40
Not applicableUnknownNCT05276713
What this trial is testing

Outcome of Tucidinostat-Based Therapy in HR+ Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Beijing 302 Hospital 50
Large-scale testing (Phase 3)Ended earlyNCT00908531
What this trial is testing

Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer

Who this might be right for
Operable Breast Neoplasms
Danish Breast Cancer Cooperative Group 123
Testing effectiveness (Phase 2)Looking for participantsNCT07708194
What this trial is testing

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

Who this might be right for
Breast CancerHER2-positive Breast CancerHormone Receptor-Positive Breast Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital 94
Early research (Phase 1)Study completedNCT03685331
What this trial is testing

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast CancerAdvanced Breast Cancer+2 more
Abramson Cancer Center at Penn Medicine 9
Large-scale testing (Phase 3)Looking for participantsNCT05950945
What this trial is testing

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Daiichi Sankyo 250
Early research (Phase 1)Study completedNCT01870505
What this trial is testing

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Metastatic or Locally-advanced Unresectable Breast Cancer
Memorial Sloan Kettering Cancer Center 52
Large-scale testing (Phase 3)Active Not RecruitingNCT06760637
What this trial is testing

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

Who this might be right for
Breast Cancer
Pfizer 1,035
Not applicableActive Not RecruitingNCT04314401
What this trial is testing

National Cancer Institute "Cancer Moonshot Biobank"

Who this might be right for
Acute Myeloid LeukemiaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+26 more
National Cancer Institute (NCI) 1,600
Testing effectiveness (Phase 2)UnknownNCT03202862
What this trial is testing

The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Fudan University 50
Early research (Phase 1)Ended earlyNCT03294694
What this trial is testing

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Who this might be right for
Metastatic Hormone-Receptor-Positive (HR+) Breast CancerHER2-Negative Breast CancerMetastatic Epithelial Ovarian Cancer
Dana-Farber Cancer Institute 33
Post-approval studies (Phase 4)Study completedNCT04707196
What this trial is testing

Abemaciclib in Indian Women With Advanced Breast Cancer

Who this might be right for
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company 200
Large-scale testing (Phase 3)Study completedNCT01942135
What this trial is testing

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Who this might be right for
Metastatic Breast Cancer
Pfizer 521
Testing effectiveness (Phase 2)UnknownNCT03492918
What this trial is testing

Pembrolizumab in Combination With Paclitaxel in the Hormone Receptor-positive Metastatic Breast Cancer With High Tumor Mutational Burden Selected by Whole Exome Sequencing: Korean Cancer Study Group Trial (KCSG BR20-16)

Who this might be right for
Metastatic Breast Cancer
Yonsei University 30
Next Page